The immunobiology and immunotherapy of ovarian cancer.
Small volume residual peritoneal disease in patients undergoing therapy for ovarian carcinoma remains an attractive, but elusive, target for immunobiological therapy. Hypothetical advantages and disadvantages of regional peritoneal therapy are being better defined through increased clinical experience and more sophisticated animal models. Developments in cytokine biology, adoptive cellular therapy, monoclonal antibody conjugation, and molecular biology continue to provide an exciting, and nearly overwhelming, array of reagents for clinical evaluation. Ongoing and anticipated investigational trials should provide intriguing data in years to follow.
Bookman
M A
MA
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Bast
R C
RC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D007376:Interleukin-2; D011868:Radioisotopes; D011994:Recombinant Proteins; D007372:Interferons